Does Tetracycline Interact with Trastuzumab Qyyp?
CDI records a major classification for Tetracycline and Trastuzumab Qyyp. The stored summary is: Patients receiving anthracyclines after stopping trastuzumab may have increased risk of cardiac dysfunction due to trastuzumab's long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab; if used, closely monitor cardiac function. The mechanism involves trastuzumab's long washout period may potentiate anthracycline-induced cardiac toxicity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Trastuzumab Qyyp Class
- HER2/neu Receptor Antagonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Trastuzumab's long washout period may potentiate anthracycline-induced cardiac toxicity
What To Tell Your Doctor or Pharmacist
If you are taking Tetracycline and your doctor is considering prescribing Trastuzumab Qyyp (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider